A Unifying Model of M.E.: An Integrated Approach to a Complex Illness

Patrick Ussher, who has recently written the book Understanding ME/CFS & Strategies for Healing, was initially inspired by the paper written by Professors Scheibenbogen and Wirth: “A Unifying Hypothesis of the Pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).” He will first outline why a unifying hypothesis is likely so crucial for clarifying the nature of ME/CFS, an illness which has often been thought to involve a range of random problems but which, according to this new German research, actually involves a clear, predictable pathophysiology comprised of many interlinking vicious cycles. 

Patrick will then give an overview of the main components of the Wirth and Scheibenbogen model, including: hypoperfusion, low blood volume, autoimmunity, cellular and autonomic dysfunction, and the precise reasons for post-exertional malaise. 

With this overview in place, Professor Klaus Wirth will then build on the explanations of Patrick’s, outlining his disease model in much greater detail, including discussion of the therapeutic he is developing (www.mitodicure.com) which he hopes will become the first medication approved specifically for ME/CFS. 

This will be a fascinating insight into this devastating condition that truly provides a unified perspective, unravelling many of its complexities.

About Patrick Ussher

Patrick Ussher is an author, composer, and ME/CFS advocate who has lived with the condition for seven years. His recent book, Understanding ME/CFS & Strategies for Healing, breaks down breakthrough research from Professors Wirth and Scheibenbogen for patient audiences, and he shares insights on treatment strategies through his YouTube channel (https://www.youtube.com/@me-cfs-strategiesforhealing) and writings for Health Rising.

About Klaus Wirth

Prof. Dr. Klaus Wirth, Medical Doctor, PhD, has served as Chief Scientific Officer and Managing Director of Mitodicure since 2022. He was previously Senior Researcher at Sanofi in Germany which he joined in 1984. Klaus worked as a pharmacologist in the fields of cardiovascular, bradykinin antagonism, cerebral blood flow, stroke, heart failure, arrhythmias, sodium-calcium exchanger NCX blockers, endocrinology, diabetes, obstructive sleep apnea, dysphagia, and immunology. Approximately 70 patents are attributable to his work, as well as five clinical developmental projects, one of which Firazyr™, a drug for the treatment of acute attacks of hereditary angioedema, has reached the market. Klaus was co-founder of KOSA Pharma GmbH. He is adjunct professor at the Institute of Pharmacology at Goethe University Frankfurt, Germany.